Eli Lilly and Company $LLY Shares Acquired by Becker Capital Management Inc.

Becker Capital Management Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 372.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 20,324 shares of the company’s stock after buying an additional 16,022 shares during the period. Becker Capital Management Inc.’s holdings in Eli Lilly and Company were worth $15,843,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Wellington Management Group LLP lifted its stake in shares of Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after purchasing an additional 81,587 shares in the last quarter. Laurel Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $8,827,714,000. Finally, Jennison Associates LLC grew its stake in shares of Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after buying an additional 226,620 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $993.51 on Thursday. The firm has a fifty day moving average of $931.98 and a two-hundred day moving average of $815.46. The firm has a market cap of $939.25 billion, a P/E ratio of 48.61, a P/E/G ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research report on Monday, November 10th. HSBC reissued a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Daiwa Capital Markets lifted their price target on shares of Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. Finally, CICC Research upped their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,109.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.